非比例危害下的治疗效果测量。

IF 1.3 4区医学 Q4 PHARMACOLOGY & PHARMACY

Pharmaceutical Statistics Pub Date : 2024-10-27 DOI:10.1002/pst.2449

Dan Jackson, Michael Sweeting, Rose Baker

{"title":"非比例危害下的治疗效果测量。","authors":"Dan Jackson, Michael Sweeting, Rose Baker","doi":"10.1002/pst.2449","DOIUrl":null,"url":null,"abstract":"'Treatment effect measures under nonproportional hazards' by Snapinn et al. (Pharmaceutical Statistics, 22, 181-193) recently proposed some novel estimates of treatment effect for time-to-event endpoints. In this note, we clarify three points related to the proposed estimators that help to elucidate their properties. We hope that their work, and this commentary, will motivate further discussion concerning treatment effect measures that do not require the proportional hazards assumption.","PeriodicalId":19934,"journal":{"name":"Pharmaceutical Statistics","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment Effect Measures Under Nonproportional Hazards.\",\"authors\":\"Dan Jackson, Michael Sweeting, Rose Baker\",\"doi\":\"10.1002/pst.2449\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"'Treatment effect measures under nonproportional hazards' by Snapinn et al. (Pharmaceutical Statistics, 22, 181-193) recently proposed some novel estimates of treatment effect for time-to-event endpoints. In this note, we clarify three points related to the proposed estimators that help to elucidate their properties. We hope that their work, and this commentary, will motivate further discussion concerning treatment effect measures that do not require the proportional hazards assumption.\",\"PeriodicalId\":19934,\"journal\":{\"name\":\"Pharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-10-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pst.2449\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pst.2449","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

Snapinn 等人的 "非比例危险下的治疗效果测量"（《医药统计》，22，181-193）最近提出了一些新的时间到事件终点治疗效果估计值。在本说明中，我们将阐明与所提估计值有关的三点，以帮助阐明其特性。我们希望他们的工作和这篇评论能激励人们进一步讨论不需要比例危险假设的治疗效果测量方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Treatment Effect Measures Under Nonproportional Hazards.

'Treatment effect measures under nonproportional hazards' by Snapinn et al. (Pharmaceutical Statistics, 22, 181-193) recently proposed some novel estimates of treatment effect for time-to-event endpoints. In this note, we clarify three points related to the proposed estimators that help to elucidate their properties. We hope that their work, and this commentary, will motivate further discussion concerning treatment effect measures that do not require the proportional hazards assumption.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmaceutical Statistics 医学-统计学与概率论

CiteScore

2.70

自引率

6.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Pharmaceutical Statistics is an industry-led initiative, tackling real problems in statistical applications. The Journal publishes papers that share experiences in the practical application of statistics within the pharmaceutical industry. It covers all aspects of pharmaceutical statistical applications from discovery, through pre-clinical development, clinical development, post-marketing surveillance, consumer health, production, epidemiology, and health economics. The Journal is both international and multidisciplinary. It includes high quality practical papers, case studies and review papers.